Epoetin-associated pure red cell aplasia: past, present, and future considerations (Q37164738)

18 August 2017

1 reference

title

Epoetin-associated pure red cell aplasia: past, present, and future considerations (English)

1 reference

18 August 2017

June M McKoy

1

1 reference

18 August 2017

Robin E Stonecash

2

1 reference

18 August 2017

Denis Cournoyer

3

1 reference

18 August 2017

Jerome Rossert

4

1 reference

18 August 2017

Allen R Nissenson

5

1 reference

18 August 2017

Dennis W Raisch

6

1 reference

18 August 2017

Nicole Casadevall

7

1 reference

18 August 2017

Charles L Bennett

8

1 reference

18 August 2017

14 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

48

1 reference

18 August 2017

8

1 reference

18 August 2017

1754-1762

1 reference

Novel erythropoiesis-stimulating agents: a new era in anemia management

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Non-clinical safety studies on biosimilar recombinant human erythropoietin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

6 September 2017

Pure red-cell aplasia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Pure red-cell aplasia and epoetin therapy.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Four cases of pure red cell aplasia secondary to epoetin beta, with strong temporal relationships.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Antibodies against rHuEPO: native and recombinant

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730535

Potential cost savings of erythropoietin administration in end-stage renal disease

3 September 2018

1 reference

12 December 2020

Pure red-cell aplasia and recombinant erythropoietin

1 reference

12 December 2020

Use of LMW heparin: information for prescribers. Update: 10 April 2002

1 reference

12 December 2020

Pure red-cell aplasia due to anti-erythropoietin antibodies

1 reference

12 December 2020

Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin

1 reference

12 December 2020

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

12 December 2020

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

12 December 2020

Autoantibodies against erythropoietin in a patient with pure red-cell aplasia

1 reference

12 December 2020

Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia

1 reference

12 December 2020

Antibodies to recombinant human erythropoietin causing pure red cell aplasia

1 reference

12 December 2020

Subcutaneous erythropoietin therapy: efficacy and economic implications

1 reference

12 December 2020

10.1111/J.1537-2995.2008.01749.X

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

1 reference